Wellcome Trust and Merck join forces to develop vaccines for low income countries

BMJ 2009; 339 doi: 10.1136/bmj.b3804 (Published 17 September 2009)
Cite this as: BMJ 2009;339:b3804

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Lynn Eaton
  1. 1London

    A leading research trust and a major drug company have launched a £90m (€100m; $150m) initiative to boost research into vaccines for diseases that are prevalent in low income countries.

    The Wellcome Trust and Merck have announced that they will jointly fund the creation of a new laboratory, to be based in India, that will develop affordable vaccine technology.

    The MSD Wellcome Trust Hilleman Laboratories will be based in India and will be equally funded by the two organisations, which will also share decision making rights in the venture. It will operate as a not for profit company, developing new vaccines and improving existing products.

    Many …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL